Fig. 1 · Structure

Documents & Downloads

Flupirtine maleate

Cat. No. A10251 CAS 75507-68-5

NMDA antagonist

Non-opioid analgesic with muscle relaxant properties.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
NMDA receptor
Potassium channel

In Vitro Studies

In cultured hippocampal neurons, Flupirtine significantly increased aIPSC charge transfer compared with solvent. In hippocampal neurons assessed for GABA-evoked currents, Flupirtine shifted the concentration–response curve leftward without changing maximal current amplitudes. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Increased aIPSC Charge Transfer in Cultured Hippocampal Neurons

Cell-based study · cultured hippocampal neurons [1]

Cultured hippocampal neurons were continuously superfused with Flupirtine at 3 and 10 μM. Flupirtine significantly increased aIPSC charge transfer compared with solvent.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
aIPSC charge transferaIPSC charge transfer 73.4 + 16.9 % (n = 6) and 141.2 + 31.3 % (n = 6)[1]

Literature-Reported Treatment Conditions

Treatment concentration
3 and 10 μM
Method
Cells were continuously superfused
Vehicle
DMSO
Co-treatment
Other interventions in this design: 1 ms depolarizations to +30 mV. Compound effect isolated by the comparison: in solvent.
Reported limits
Not stated in the sentences used: schedule.
Methods and source locations

Compound reported in the paper: Flupirtine

The paper names Flupirtine without stating the salt or form; not verified as the maleate form supplied as A10251. No dose conversion or lot validation.

Methods > Electrophysiology (S29, S30, S37); Results > Flupirtine prolongs autaptic inhibitory postsynaptic currents but does not affect mIPSCs, in hippocampal neurons (S90); Figure 4 legend (S177, S178, S181)

aIPSC charge transfer: aIPSC charge transfer; comparator: in solvent — Results > Flupirtine prolongs autaptic inhibitory postsynaptic currents but does not affect mIPSCs, in hippocampal neurons (S90); Figure 4 legend (S181)

Altered GABA Concentration–Response Relationship in Hippocampal Neurons

Cell-based study · hippocampal neurons [1]

Hippocampal neurons were continuously superfused with Flupirtine at 30 μM during assessment of GABA-evoked currents. Compared with solvent, Flupirtine shifted the concentration–response curve leftward without changing maximal current amplitudes; the reported EC50 was 3.5 ± 0.5 μM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
EC50 (μM)EC50 Hippocampus; Flupirtine (30 μM): EC50 = 3.5 ± 0.5 μM[1]

Literature-Reported Treatment Conditions

Treatment concentration
30 μM
Exposure duration
at least 10 s before and after co-application
Method
Cells were continuously superfused
Vehicle
0.1% DMSO
Co-treatment
Other interventions in this design: GABA. Compound effect isolated by the comparison: solvent (0.1% DMSO).
Methods and source locations

Compound reported in the paper: Flupirtine

The paper names Flupirtine without stating the salt or form; not verified as the maleate form supplied as A10251. No dose conversion or lot validation.

Methods > Electrophysiology (S34, S37); Results > Flupirtine differentially modulates currents through GABAA receptors involved in phasic and tonic inhibition respectively (S106, S107, S108, S109); Figure 6 legend (S148, S151); Table 1 (T3.h1, T3.h2, T3.r1)

EC50 (μM): EC50 (μM); comparator: solvent (0.1% DMSO) — Results > Flupirtine differentially modulates currents through GABAA receptors involved in phasic and tonic inhibition respectively (S107, S108, S109); Table 1 (T3.h1, T3.h2, T3.r1)

In Vivo Studies

In adult male Sprague‐Dawley rats with lithium/pilocarpine‐induced ESE, Flupirtine did not reduce mean SE duration compared with saline control treatment. In hypoxia-exposed male Wistar rats receiving Flupirtine maleate by gavage, the isolated-lung P/Q slope was 0.475 ± 0.022 mmHg·min/ml, with a reported difference versus hypoxia and hypoxia with vehicle. [2,3]

Flupirtine treatment alone did not effectively treat lithium/pilocarpine‐induced ESE

Animal study · Adult male Sprague‐Dawley rats; lithium/pilocarpine‐induced ESE [2]

Adult male Sprague‐Dawley rats with lithium/pilocarpine‐induced ESE received Flupirtine at 50 mg/kg i.p. Compared with saline control treatment, Flupirtine did not reduce mean SE duration, reported as 7.86 ± 1.5 h.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
mean SE durationmean SE duration 7.86 ± 1.5 h[2]

Conditions shared by the study groups

Route
i.p.
Treatment course
10 min after the onset of continuous electrographic seizure activity
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Flupirtine 50 mg/kgsaline control treatmentFlupirtine (50 mg/kg) also did not reduce the mean SE duration (7.86 ± 1.5 h, P > 0.05, Fig. 2C).[2]
Flupirtine 50 mg/kg
Model: Adult male Sprague‐Dawley rats; lithium/pilocarpine‐induced ESE
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Flupirtine

The paper names Flupirtine without stating the salt or form; not verified as the maleate form supplied as A10251. No dose conversion or lot validation.

Methods (S2, S3); Methods > Lithium/pilocarpine method (S6, S7); Methods > DFP (S27); Results (S35, S36, S37, S38); Figure 2 legend (S72, S75); Figure 3 legend (S85)

mean SE duration: mean SE duration; comparator: saline control treatment — Results (S38)

Flupirtine 50 mg/kg · Results (S35, S36, S38)

Pulmonary Pressure–Flow Relationship in Hypoxia-Exposed Rats

Animal study · male Wistar rats [3]

Male Wistar rats exposed to hypoxia received Flupirtine maleate at 15 mg/kg by gavage. The hypoxia-plus-flupirtine group had an isolated-lung P/Q slope of 0.475 ± 0.022 mmHg·min/ml, with a reported difference versus hypoxia and hypoxia with vehicle.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
P/Q relationship and vascular reactivity measured in isolated lungs.P/Q slope 0.475 ± 0.022 mmHg·min/ml[3]

Conditions shared by the study groups

Route
by gavage
Treatment course
Groups of rats were exposed to an hypoxic environment by maintaining them in an isobaric hypoxic chamber (FiO2 0.1) for 5 days (14). One group of rats exposed to hypoxia was administered flupirtine 15 mg/kg twice a day by gavage (n = 6) throughout the exposure period.
Vehicle
dimethyl sulfoxide (DMSO)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Flupirtine maleate 15 mg/kgHypoxia + vehicleHypoxia + flupirtine; 5-day hypoxia and oral flupirtine treatment (30 mg/kg/day): P/Q Slope, mmHg·min/ml: 0.475 ± 0.022†. †P < 0.05 vs. hypoxia and hypoxia with vehicle; n = 6 for each group.[3]
Flupirtine maleate 15 mg/kg
Model: male Wistar rats
Methods and source locations

Compound reported in the paper: Flupirtine maleate; Compound label in the paper: Flupirtine

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

METHODS (S1); METHODS > Untitled > In vivo treatment. (S40, S42, S43); RESULTS > Untitled > Flupirtine inhibits hypoxic pulmonary hypertension. (S124); Table 2. legend (S158); Table 2. (T2.h1, T2.r3, T2.r4)

P/Q relationship and vascular reactivity measured in isolated lungs.: P/Q relationship and vascular reactivity measured in isolated lungs.; comparator: Hypoxia + vehicle — RESULTS > Untitled > Flupirtine inhibits hypoxic pulmonary hypertension. (S124); Table 2. legend (S158); Table 2. (T2.h1, T2.r3)

Flupirtine maleate 15 mg/kg · METHODS > Untitled > In vivo treatment. (S40, S42); RESULTS > Untitled > Flupirtine inhibits hypoxic pulmonary hypertension. (S124); Table 2. legend (S158); Table 2. (T2.h1, T2.r3)

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 75507-68-5
Applications NMDA antagonist
Formula C15H17FN4O2.C4H4O4
Molecular Weight 420.4
Synonyms D 9998
SMILES
CCOC(=O)NC1=C(N=C(C=C1)NCC2=CC=C(C=C2)F)N.C(=C\C(=O)O)\C(=O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 76 mg/mL (180.78 mM)
Water Insoluble
Ethanol Warmed: 2 mg/mL (4.75 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
30% propylene glycol, 5% Tween 80, 65% D5W

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Klinger F, Bajric M, Salzer I, et al. δ Subunit-containing GABAA receptors are preferred targets for the centrally acting analgesic flupirtine. Br J Pharmacol (2015). PMID: 26211808 DOI: 10.1111/bph.13262 Source material
  2. [2] Zhang T, Todorovic MS, Williamson J, et al. Flupirtine and diazepam combination terminates established status epilepticus: results in three rodent models. Ann Clin Transl Neurol (2017). PMID: 29296617 DOI: 10.1002/acn3.497 Source material
  3. [3] Sedivy V, Joshi S, Ghaly Y, et al. Role of Kv7 channels in responses of the pulmonary circulation to hypoxia. Am J Physiol Lung Cell Mol Physiol (2015). PMID: 25361569 DOI: 10.1152/ajplung.00362.2013 Source material

Added to your cart

View Cart Checkout
Loading...